Cargando…

Application of the Filariasis CELISA Antifilarial IgG(4) Antibody Assay in Surveillance in Lymphatic Filariasis Elimination Programmes in the South Pacific

Elimination of lymphatic filariasis (LF) in the Pacific Island Countries and Territories (PICT) has been defined as <0.1% circulating filarial antigen (CFA) prevalence in children born after the implementation of successful mass drug administrations (MDAs). This research assessed the feasibility...

Descripción completa

Detalles Bibliográficos
Autores principales: Joseph, Hayley, Maiava, Fuatai, Naseri, Take, Taleo, Fasihah, ‘Ake, Malakai, Capuano, Corinne, Melrose, Wayne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180782/
https://www.ncbi.nlm.nih.gov/pubmed/21961018
http://dx.doi.org/10.1155/2011/492023
_version_ 1782212695252008960
author Joseph, Hayley
Maiava, Fuatai
Naseri, Take
Taleo, Fasihah
‘Ake, Malakai
Capuano, Corinne
Melrose, Wayne
author_facet Joseph, Hayley
Maiava, Fuatai
Naseri, Take
Taleo, Fasihah
‘Ake, Malakai
Capuano, Corinne
Melrose, Wayne
author_sort Joseph, Hayley
collection PubMed
description Elimination of lymphatic filariasis (LF) in the Pacific Island Countries and Territories (PICT) has been defined as <0.1% circulating filarial antigen (CFA) prevalence in children born after the implementation of successful mass drug administrations (MDAs). This research assessed the feasibility of CFA and antibody testing in three countries; Tonga, Vanuatu, and Samoa. Transmission is interrupted in Vanuatu and Tonga as evidenced by no CFA positive children and a low antibody prevalence and titre. Transmission is ongoing in Samoa with microfilaraemic (Mf) and CFA positive children and a high antibody prevalence and titre. Furthermore, areas of transmission were identified with Mf positive adults, but no CFA positive children. These areas had a high antibody prevalence in children. In conclusion, CFA testing in children alone was not useful for identifying areas of residual endemicity in Samoa. Thus, it would be beneficial to include antibody serology in the PICT surveillance strategy.
format Online
Article
Text
id pubmed-3180782
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31807822011-09-29 Application of the Filariasis CELISA Antifilarial IgG(4) Antibody Assay in Surveillance in Lymphatic Filariasis Elimination Programmes in the South Pacific Joseph, Hayley Maiava, Fuatai Naseri, Take Taleo, Fasihah ‘Ake, Malakai Capuano, Corinne Melrose, Wayne J Trop Med Research Article Elimination of lymphatic filariasis (LF) in the Pacific Island Countries and Territories (PICT) has been defined as <0.1% circulating filarial antigen (CFA) prevalence in children born after the implementation of successful mass drug administrations (MDAs). This research assessed the feasibility of CFA and antibody testing in three countries; Tonga, Vanuatu, and Samoa. Transmission is interrupted in Vanuatu and Tonga as evidenced by no CFA positive children and a low antibody prevalence and titre. Transmission is ongoing in Samoa with microfilaraemic (Mf) and CFA positive children and a high antibody prevalence and titre. Furthermore, areas of transmission were identified with Mf positive adults, but no CFA positive children. These areas had a high antibody prevalence in children. In conclusion, CFA testing in children alone was not useful for identifying areas of residual endemicity in Samoa. Thus, it would be beneficial to include antibody serology in the PICT surveillance strategy. Hindawi Publishing Corporation 2011 2011-09-26 /pmc/articles/PMC3180782/ /pubmed/21961018 http://dx.doi.org/10.1155/2011/492023 Text en Copyright © 2011 Hayley Joseph et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Joseph, Hayley
Maiava, Fuatai
Naseri, Take
Taleo, Fasihah
‘Ake, Malakai
Capuano, Corinne
Melrose, Wayne
Application of the Filariasis CELISA Antifilarial IgG(4) Antibody Assay in Surveillance in Lymphatic Filariasis Elimination Programmes in the South Pacific
title Application of the Filariasis CELISA Antifilarial IgG(4) Antibody Assay in Surveillance in Lymphatic Filariasis Elimination Programmes in the South Pacific
title_full Application of the Filariasis CELISA Antifilarial IgG(4) Antibody Assay in Surveillance in Lymphatic Filariasis Elimination Programmes in the South Pacific
title_fullStr Application of the Filariasis CELISA Antifilarial IgG(4) Antibody Assay in Surveillance in Lymphatic Filariasis Elimination Programmes in the South Pacific
title_full_unstemmed Application of the Filariasis CELISA Antifilarial IgG(4) Antibody Assay in Surveillance in Lymphatic Filariasis Elimination Programmes in the South Pacific
title_short Application of the Filariasis CELISA Antifilarial IgG(4) Antibody Assay in Surveillance in Lymphatic Filariasis Elimination Programmes in the South Pacific
title_sort application of the filariasis celisa antifilarial igg(4) antibody assay in surveillance in lymphatic filariasis elimination programmes in the south pacific
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180782/
https://www.ncbi.nlm.nih.gov/pubmed/21961018
http://dx.doi.org/10.1155/2011/492023
work_keys_str_mv AT josephhayley applicationofthefilariasiscelisaantifilarialigg4antibodyassayinsurveillanceinlymphaticfilariasiseliminationprogrammesinthesouthpacific
AT maiavafuatai applicationofthefilariasiscelisaantifilarialigg4antibodyassayinsurveillanceinlymphaticfilariasiseliminationprogrammesinthesouthpacific
AT naseritake applicationofthefilariasiscelisaantifilarialigg4antibodyassayinsurveillanceinlymphaticfilariasiseliminationprogrammesinthesouthpacific
AT taleofasihah applicationofthefilariasiscelisaantifilarialigg4antibodyassayinsurveillanceinlymphaticfilariasiseliminationprogrammesinthesouthpacific
AT akemalakai applicationofthefilariasiscelisaantifilarialigg4antibodyassayinsurveillanceinlymphaticfilariasiseliminationprogrammesinthesouthpacific
AT capuanocorinne applicationofthefilariasiscelisaantifilarialigg4antibodyassayinsurveillanceinlymphaticfilariasiseliminationprogrammesinthesouthpacific
AT melrosewayne applicationofthefilariasiscelisaantifilarialigg4antibodyassayinsurveillanceinlymphaticfilariasiseliminationprogrammesinthesouthpacific